Literature DB >> 25149352

The innate immune response status correlates with a divergent clinical course in congenital Chagas disease of twins born in a non-endemic country.

Ana Fernández-Villegas1, M Carmen Thomas1, Bartolomé Carrilero2, Cinta Téllez3, Concepción Marañón1, Laura Murcia2, Sara Moralo3, Carlos Alonso4, Manuel Segovia5, Manuel Carlos López6.   

Abstract

The innate immune response from diamniotic and dichorionic twin brothers congenitally infected with Trypanosoma. cruzi (strain DTU-V) who displayed different clinical symptomatology was studied. While Brother I manifested severe cardiac and digestive disorders, the Brother II showed slight splenomegaly. The secretion level of IL-1β, TNF-α, IL-12, IL-10, IFN-α and IL-6 cytokines produced after stimulation of peripheral blood cells with TLR-2, TLR-4 and TLR-9 ligands was determined pre- and post-benznidazole treatment. Cells from 10 uninfected infants born to mothers seropositive for Chagas disease were included as control. The obtained data show that the cells of Brother I secreted lower levels of the pro-inflammatory cytokines IL-1β and TNF-α (upon TLR-2 and TLR-4 stimulation) relative to those secreted by cells from Brother II and uninfected controls. The cells from Brother II secreted high levels of the IL-1β cytokine following TLR-2 stimulation relative to uninfected controls. The cells from both brothers secreted a higher level of IL-6, following TLR-4 stimulation, than that secreted by uninfected infant cells. After treatments, the cytokine secretion levels were similar in both children and comparable to those of uninfected donors. Treatment success in Brother I and treatment interruption in Brother II was detected by the use of serological biomarkers (KMP11, HSP70, PFR2, Tgp63) as well as follow-up done by PCR. Therefore, the Brother II required a second treatment. The data presented suggest that benznidazol treatment allows the innate immune system to reach a fully functional status similar to that of uninfected subjects.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chagas disease; Congenital transmission; Innate immune response; PCR; Serological biomarker; Trypanosoma cruzi

Mesh:

Substances:

Year:  2014        PMID: 25149352     DOI: 10.1016/j.actatropica.2014.08.006

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  3 in total

Review 1.  Biomarkers of therapeutic responses in chronic Chagas disease: state of the art and future perspectives.

Authors:  Maria-Jesus Pinazo; Maria-Carmen Thomas; Juan Bustamante; Igor Correia de Almeida; Manuel-Carlos Lopez; Joaquim Gascon
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-04-28       Impact factor: 2.743

2.  Expression of inhibitory receptors and polyfunctional responses of T cells are linked to the risk of congenital transmission of T. cruzi.

Authors:  Adriana Egui; Paola Lasso; María Carmen Thomas; Bartolomé Carrilero; John Mario González; Adriana Cuéllar; Manuel Segovia; Concepción Judith Puerta; Manuel Carlos López
Journal:  PLoS Negl Trop Dis       Date:  2017-06-09

3.  New chemotherapy regimens and biomarkers for Chagas disease: the rationale and design of the TESEO study, an open-label, randomised, prospective, phase-2 clinical trial in the Plurinational State of Bolivia.

Authors:  Cristina Alonso-Vega; Julio A Urbina; Sergi Sanz; María-Jesús Pinazo; Jimy José Pinto; Virginia R Gonzalez; Gimena Rojas; Lourdes Ortiz; Wilson Garcia; Daniel Lozano; Dolors Soy; Rosa A Maldonado; Rana Nagarkatti; Alain Debrabant; Alejandro Schijman; M Carmen Thomas; Manuel Carlos López; Katja Michael; Isabela Ribeiro; Joaquim Gascon; Faustino Torrico; Igor C Almeida
Journal:  BMJ Open       Date:  2021-12-31       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.